Compare CVGI & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVGI | CVM |
|---|---|---|
| Founded | 2000 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.7M | 53.1M |
| IPO Year | 2004 | 1987 |
| Metric | CVGI | CVM |
|---|---|---|
| Price | $1.44 | $5.26 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 105.4K | 74.9K |
| Earning Date | 11-10-2025 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $657,532,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.32 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.81 | $1.98 |
| 52 Week High | $2.55 | $20.41 |
| Indicator | CVGI | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 45.62 | 40.00 |
| Support Level | $1.41 | $4.01 |
| Resistance Level | $1.52 | $5.67 |
| Average True Range (ATR) | 0.09 | 0.49 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 37.50 | 43.43 |
Commercial Vehicle Group Inc is a provider of systems, assemblies, and components to the commercial vehicle market and the electric vehicle markets. It delivers solutions to complex design, engineering, and manufacturing problems while creating positive change for customers, industries, and communities. Its operating segments are Vehicle Solutions, Electrical Systems, and Aftermarket and Accessories. The company makes the majority of its revenue from Vehicle Solutions. The group generates revenue from its products including seating systems, plastic components, electrical wire harnesses, mirrors, wipers, and other accessories. Its geographic regions are North America, Europe and Asia-Pacific.
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.